Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1521 to 1530 of 2636 total matches.
Pharmacogenetic-Based Dosing of Warfarin
The Medical Letter on Drugs and Therapeutics • May 19, 2008 (Issue 1286)
and overanticoagulation can lead to hemorrhage.
1
Genotyping patients for
single nucleotide polymorphisms (SNPs ...
Warfarin sodium (Coumadin, and others) and other coumarin anticoagulants prevent thrombosis, but patient response is highly variable and overanticoagulation can lead to hemorrhage. Genotyping patients for single nucleotide polymorphisms (SNPs) that affect coumarin metabolism and sensitivity may help clinicians estimate the therapeutic warfarin dose. The FDA has added a note to warfarin labeling recommending lowrange doses for patients with such genetic variations. Commercial tests for these variants are now available and cost about $500 per test.
Robotic-Assisted Laparoscopic Surgery
The Medical Letter on Drugs and Therapeutics • Jun 14, 2010 (Issue 1340)
than traditional
laparoscopic procedures.
1,2
THE DEVICE — The da Vinci Surgical System consists ...
The da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA) has become available in recent years
for use in laparoscopic prostatectomy, gynecological procedures, general surgery, otolaryngology and cardiothoracic procedures.
Namzaric - A Combination of 2 Old Drugs for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Jul 20, 2015 (Issue 1473)
or reverse the underlying neurodegenerative
process.1
Many patients with moderate to severe AD are
treated ...
The FDA has approved Namzaric (Forest), a fixed-dose
combination of extended-release (ER)
memantine (Namenda XR), an NMDA-receptor
antagonist, and donepezil (Aricept, and generics),
an acetylcholinesterase inhibitor, for treatment of
moderate to severe Alzheimer's type dementia in
patients previously stabilized on both drugs. The
patent for Namenda has recently expired and generic
formulations of memantine 5- and 10-mg tablets have
been approved.
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)1 ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...
Expanded Indication for PCSK9 Inhibitors
The Medical Letter on Drugs and Therapeutics • Dec 22, 2025 (Issue 1744)
). They reduce LDL-C levels by
about 55-60% when used alone or with a HMG-CoA
reductase inhibitor (statin).1 ...
The FDA has approved changes to the wording of
the cardiovascular risk reduction indications for
the proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors evolocumab (Repatha) and
alirocumab (Praluent). Both drugs are now approved
to reduce the risk of major adverse cardiovascular
events (MACE) in adults at increased risk for these
events; they were previously approved to reduce
the risk of MACE only in patients with established
cardiovascular disease (CVD).
Med Lett Drugs Ther. 2025 Dec 22;67(1744):201-3 doi:10.58347/tml.2025.1744a | Show Introduction Hide Introduction
Who Should Take Vitamin Supplements?
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
providers whether
they should take vitamins. Since the last Medical Letter
article on this subject,1 more ...
Many patients ask their healthcare providers whether
they should take vitamins. Since the last Medical Letter
article on this subject, more data have become available
on the benefits and risks of taking vitamins.
In Brief: Recommendation for Earlier Antibiotic Prophylaxis for Cesarean Delivery
The Medical Letter on Drugs and Therapeutics • Oct 04, 2010 (Issue 1348)
prophylaxis during
cesarean delivery.1 Currently most women receive a
single dose of prophylactic ...
The American Congress of Obstetricians and Gynecologists (ACOG) has announced a new recommendation for antibiotic prophylaxis during cesarean delivery.1 Currently most women receive a single dose of prophylactic antibiotics after the umbilical cord has been clamped to prevent antibiotics from crossing over to the newborn. The new recommendation is for women giving birth by cesarean section to routinely receive antibiotics within one hour before the start of surgery. In the case of an emergency cesarean delivery, prophylaxis should be started as soon as possible.Recent studies have found a...
Addendum: Ospemifene (Osphena) for Dyspareunia
The Medical Letter on Drugs and Therapeutics • Oct 14, 2013 (Issue 1427)
also take a progestin.1 Ospemifene has agonistic
effects on the endometrium, and the Osphena
package ...
Some readers have objected to our recommendation (Med Lett Drugs Ther 2013; 55:55) that postmenopausal women with an intact uterus who take the oral estrogen agonist/antagonist ospemifene (Osphena) to reduce the severity of dyspareunia should also take a progestin.1 Ospemifene has agonistic effects on the endometrium, and the Osphena package insert says: "Generally, when a product with estrogen agonistic effects on the endometrium is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer."Endometrial hyperplasia has been...
In Brief: Ponatinib (Iclusig) Marketing and Sales Suspended
The Medical Letter on Drugs and Therapeutics • Nov 25, 2013 (Issue 1430)
narrowing of blood
vessels.1 Ponatinib is a tyrosine kinase inhibitor that
was granted accelerated ...
The FDA recently issued a Drug Safety Communication saying that it had asked the manufacturer of ponatinib (Iclusig – Ariad) to suspend marketing and sales of the drug because of the risk of life-threatening blood clots and severe narrowing of blood vessels.1 Ponatinib is a tyrosine kinase inhibitor that was granted accelerated approval by the FDA in December 2012 for treatment of chronic-, accelerated, or blast-phase chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant to (or the patients were intolerant to) prior tyrosine...
Mumps Outbreak
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014 (Issue 1438)
by a rapid decline in the incidence of disease.1,2
RECOMMENDATIONS — During a mumps outbreak, the
Advisory ...
An outbreak of mumps has occurred among students at
Fordham University in New York. All of those who developed
mumps had been vaccinated against the disease.
